Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Danielle Bagarry-Liegey"'
Autor:
Danielle Bagarry-Liegey, Bruno Lacarelle, Rose-Marie Ferri-Dessens, Florence Duffaud, M. Zanaret, Nicolas Frances, Cédric Mercier, Antoine Giovanni, Jean-François Seitz, Arthur Varoquaux, Hafedh Marouani, Joseph Ciccolini, Caroline Brunet, A. Blesius, Roger Favre, Mohamed Chefrour, Chen Guang Yang, Laetitia Dahan
Publikováno v:
Cancer Chemotherapy and Pharmacology. 67:49-56
Fluoropyrimidine drugs are widely used in head and neck cancer (HNC). DPD deficiency is a pharmacogenetics syndrome associated with severe/lethal toxicities upon 5-FU or capecitabine intake. We have developed a simple, rapid, and inexpensive function
Autor:
Charlotte Dupuis, Athanassios Iliadis, Chenguang Yang, Florence Duffaud, Joseph Ciccolini, Bertrand Pourroy, Suzanne Monjanel-Mouterde, Roger Favre, Jean-Laurent Deville, Raphaelle Fanciullino, Danielle Bagarry-Liegey, Alain Durand, Cédric Mercier
Publikováno v:
Anti-cancer drugs. 19(3)
Preoperative high-dose methotrexate (HD-MTX) with folinic acid (leucovorin) rescue is still a mainstay in the treatment of osteosarcoma. This anticancer agent is characterized by a narrow therapeutic index and wide interpatients variability. To ensur
Autor:
Raphaelle Fanciullino, Adriana E. Nicoara, Alex Noble, Joseph Ciccolini, Brigitte Tranchand, Bruno Lacarelle, Suzanne Monjanel-Mouterde, Marjorie Baciuchka, Bertrand Pourroy, Pierre Guillet, Florence Duffaud, Alain Durand, Roger Favre, Cédric Mercier, Laurence Digue, Danielle Bagarry-Liegey
Publikováno v:
Therapeutic Drug Monitoring
Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2006, 28(2), pp.212-8
Therapeutic Drug Monitoring, 2006, 28(2), pp.212-8
Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2006, 28(2), pp.212-8
Therapeutic Drug Monitoring, 2006, 28(2), pp.212-8
Carboplatin (CBDCA) is a widely used anticancer agent for which dose-effect and dose-toxicity relationships have been demonstrated, thus stressing the need for a controlled exposure to this drug. So far, carboplatin administration could only be indiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9674f8379c72a5fbf24e7b8c17aa5ea1
https://hal.archives-ouvertes.fr/hal-00077421
https://hal.archives-ouvertes.fr/hal-00077421
Autor:
A Durand, Roger Favre, Danielle Bagarry-Liegey, Jacques Catalin, P. Guillet, A. Nicoara, Bruno Lacarelle, Florence Duffaud, S. Monjanel
Publikováno v:
Cancer chemotherapy and pharmacology. 40(2)
Carboplatin (CBDCA), an analogue of cisplatin, exhibits reduced toxicity but wide interpatient variability of its pharmacokinetic parameters. Individualization of the CBDCA dose is therefore necessary. Although various formulas have been developed fo
Autor:
Bruno Lacarelle, Antoine Giovanni, S. Duflo, Caroline Brunet, Danielle Bagarry-Liegey, Florence Duffaud, Charlotte Dupuis, J. Ciccolini, Chenguang Yang, Cédric Mercier, M. Zanaret
Publikováno v:
Journal of Clinical Oncology. 27:6515-6515
6515 Background: Dihydropyrimidine dehydrogenase (DPD) plays a pivotal role in the detoxification of 5-FU. We studied the impact of screening DPD impairment in head and neck cancer (HNC) patients, both on reduction of drug-related toxicities and as a
Autor:
M. Zanaret, Bruno Lacarelle, Chenguang Yang, Danielle Bagarry-Liegey, Charlotte Dupuis, Laetitia Padovani, Cédric Mercier, R. Favre, J. Ciccolini, Florence Duffaud, C. Rosca
Publikováno v:
Journal of Clinical Oncology. 26:14556-14556
14556 Background: DPD deficiency is a pharmacogenetics syndrome associated with severe/lethal toxicities upon 5-FU intake. We previously developed a rapid and cost-effective phenotypic method for D...